Prognostic significance of endogenous erythropoietin in long-term outcome of patients with acute decompensated heart failure

European Journal of Heart Failure

Volumn 18, Issue 7, 2016, Pages 803-813

  Nagai, Toshiyuki ^a   Nishimura, Kunihiro ^a   Honma, Takehiro ^a   Higashiyama, Aya ^a   Sugano, Yasuo ^a   Nakai, Michikazu ^a   Honda, Satoshi ^a   Iwakami, Naotsugu ^a   Okada, Atsushi ^a   Kawakami, Shoji ^a   Kanaya, Tomoaki ^a   Asaumi, Yasuhide ^a   Aiba, Takeshi ^a   Nishida, Yoko ^b   Kubota, Yoshimi ^c   Sugiyama, Daisuke ^d   Okamura, Tomonori ^d   Noguchi, Teruo ^a   Kusano, Kengo ^a   Ogawa, Hisao ^a   Yasuda, Satoshi ^a   Anzai, Toshihisa ^a   more..

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d KEIO UNIVERSITY   (Japan)

Author keywords

Acute heart failure; Anaemia; Biomarker; Erythropoietin; Prognosis

Indexed keywords

ALBUMIN; BRAIN NATRIURETIC PEPTIDE; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; IRON; LACTIC ACID; SODIUM;

ACUTE HEART FAILURE; ADVERSE OUTCOME; AGED; ANALYTICAL PARAMETERS; ANEMIA; ARTICLE; COHORT ANALYSIS; DISEASE MARKER; DISEASE SEVERITY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; LACTATE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OXYGEN SATURATION; PLASMA VOLUME; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; TRANSFERRIN SATURATION;

EID: 84978976687     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.537     Document Type: Article

References (29)

1. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397–1402.
2. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003;107:223–225.
3. Breunig F, Wanner C. Enzyme replacement therapy for Fabry disease: proving the clinical benefit. Nephrol Dial Transplant 2003;18:7–9.
4. Silverberg DS, Wexler D, Iaina A, Steinbruch S, Wollman Y, Schwartz D. Anemia, chronic renal disease and congestive heart failure—the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. Int Urol Nephrol 2006;38:295–310.
5. Cazzola M, Mercuriali F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood 1997;89:4248–4267.
6. van der Meer P, Voors AA, Lipsic E, Smilde TD, van Gilst WH, van Veldhuisen DJ. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 2004;44:63–67.
7. Belonje AM, Westenbrink BD, Voors AA, von Haehling S, Ponikowski P, Anker SD, van Veldhuisen DJ, Dickstein K. Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan. Am Heart J 2009;157:91–96.
8. George J, Patal S, Wexler D, Abashidze A, Shmilovich H, Barak T, Sheps D, Keren G. Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. Arch Intern Med 2005;165:1304–1309.
9. Belonje AM, Voors AA, van Gilst WH, van Veldhuisen DJ. Erythropoietin in chronic heart failure. Congest Heart Fail 2007;13:289–292.
10. Belonje AM, Voors AA, van der Meer P, van Gilst WH, Jaarsma T, van Veldhuisen DJ. Endogenous erythropoietin and outcome in heart failure. Circulation 2010;121:245–251.
11. Diskin CJ. Erythropoietin, haemoglobin, heart failure, and mortality. Eur Heart J 2008;29:2695; author reply 2695–2696.
12. Anand IS. Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol 2008;52:501–511.
13. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971;285:1441–1446.
14. Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 2006;114:1572–1580.
15. van der Meer P, Lok DJ, Januzzi JL, de la Porte PW, Lipsic E, van Wijngaarden J, Voors AA, van Gilst WH, van Veldhuisen DJ. Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. Eur Heart J 2008;29:1510–1515.
16. Beguin Y, Clemons GK, Pootrakul P, Fillet G. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 1993;81:1067–1076.
17. Lee G, ed. Anemia: General Aspects. 10th ed. Williams & Wilkins; 1999.
18. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436–2448.
19. Feldschuh J, Enson Y. Prediction of the normal blood volume. Relation of blood volume to body habitus. Circulation 1977;56:605–612.
20. Takei M, Kohsaka S, Shiraishi Y, Goda A, Izumi Y, Yagawa M, Mizuno A, Sawano M, Inohara T, Kohno T, Fukuda K, Yoshikawa T. Effect of estimated plasma volume reduction on renal function for acute heart failure differs between patients with preserved and reduced ejection fraction. Circ Heart Fail 2015;8:527–532.
21. Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC; PROTECT Investigators and Committees. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010;363:1419–1428.
22. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF, Jr., Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M; RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381:29–39.
23. Asaumi Y, Kagaya Y, Takeda M, Yamaguchi N, Tada H, Ito K, Ohta J, Shiroto T, Shirato K, Minegishi N, Shimokawa H. Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice. Circulation 2007;115:2022–2032.
24. Westenbrink BD, Lipsic E, van der Meer P, van der Harst P, Oeseburg H, Du Marchie Sarvaas GJ, Koster J, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 2007;28:2018–2027.
25. van der Meer P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005;46:125–133.
26. Lipsic E, Westenbrink BD, van der Meer P, van der Harst P, Voors AA, van Veldhuisen DJ, Schoemaker RG, van Gilst WH. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail 2008;10:22–29.
27. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ; RED-HF Committees; RED-HF Investigators. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013;368:1210–1219.
28. Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P; Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008; 117:526–535.
29. Grote Beverborg N, van der Wal HH, Klip IT, Voors AA, de Boer RA, van Gilst WH, van Veldhuisen DJ, Gansevoort RT, Hillege HL, van der Harst P, Bakker SJ, van der Meer P. High serum erythropoietin levels are related to heart failure development in subjects from the general population with albuminuria: data from PREVEND. Eur J Heart Fail 2016;18:814–821.